Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis.

ABSTRACT:

Background

Fatigue is one of the most common adverse effects associated with cancer immunotherapy using checkpoint inhibitors (CPIs). Because treatment-related fatigue also frequently occurs in patients treated with non-immunological therapies, our study aimed to compare the incidence of fatigue in CPI-treated patients with that associated with non-immune therapies in randomised trials.

Methods

PubMed and ClinicalTrials.gov were searched for phase III studies using a CPI alone or in combination with chemotherapy or non-immunologic targeted therapy in the experimental arm and control arm using inactive therapies such as placebo or observation, chemotherapy, or non-immunologic targeted therapy. Adverse events listed in the full texts as well as those available from clinicaltri

SUBMITTER: Kiss I 

PROVIDER: S-EPMC9271472 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature